



SA 10/607,890


PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: CARTER et al. Examiner: unknown  
Serial No.: 10/607,890 Group Art Unit: 1614  
Filed: 27 June 2003 Docket No.: 3955.124USU1  
Title: GLYCOALKALOID COMPOSITIONS AND VARIOUS USES THEREOF

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Mail Stop MISSING PARTS, P.O. Box 1450, Alexandria, VA 22313-1450 on October 27, 2003.

  
Name: Heidi McCarty

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop MISSING PARTS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked

as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Dated: 27 October 2003

By Brian H. Batzli  
Reg. No. 32,960

BHB:hjm

**23552**

PATENT TRADEMARK OFFICE

FORM 1449* INFORMATION DISCLOSURE STATEMENT  IN AN APPLICATION  <small>(or several sheets if necessary)</small>		Docket Number: 3955.124USU1	Application Number: 10/607,890
		Applicant: CARTER et al.	
		Filing Date: 27 June 2003	Group Art Unit: 1614



U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
	AU-B-57853/80	6 Nov. 1980	Australia			
	WO 91/10743	25 July 1991	WIPO			
	WO 00/61153	19 Oct. 2000	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
		CHAM. "Solasodine glycosides as anti-cancer agents: pre-clinical and clinical studies". <i>Asia Pacific Journal of Pharmacology</i> , Vol. 9, pp. 113-118 (1994).				
		GHOSH et al. "Antifilarian effect of solamargine isolated from <i>Solanum khasianum</i> ". <i>Int. Journal Pharmacog.</i> , Vol. 32, No. 2, pp. 184-190 (1994).				
		CHAM et al. "Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides". <i>Cancer Letters</i> , Vol. 59, pp. 183-192 (1991).				
		DAUNTER et al. "Solasodine glycosides. In vitro preferential cytotoxicity for human cancer cells". <i>Cancer Letters</i> , Vol. 55, pp. 209-220 (1990).				



EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	